Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Mesothelioma, Malignant 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

X-Rays 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Phantoms, Imaging 6Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4cixutumumab 3cabozantinib 3Temozolomide 3Leucovorin 3Filgrastim 3Cyclophosphamide 3Cisplatin 3ulixertinib 2tipifarnib 2temsirolimus 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2merphos 2larotrectinib 2ixabepilone 2ivosidenib 2ensartinib 2dinutuximab 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Osteosarcoma × alanosine × Clear all
NCT00062283 2013-06-26

Alanosine in Treating Patients With Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡